Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10473975 | 0.89 | MAPT (0.50) | MAPTPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL5062383 | 0.88 | MAPT (0.52) | MAPTCYP1A2ALDH1A1TDP1LMNA | |
| SCHEMBL21824100 | 0.86 | ALDH1A1 (0.59) | MAPTCYP1A2ALDH1A1TDP1LMNA | |
| SCHEMBL13400411 | 0.86 | TSHR (0.49) | MAPTCYP1A2PDGFRBFGFR1PDGFRA | |
| SCHEMBL27719772 | 0.86 | PDGFRB (0.56) | MAPTCYP1A2PDGFRBFGFR1PDGFRA | |
| SCHEMBL10653936 | 0.85 | MAPT (0.49) | MAPTCYP1A2ALDH1A1TDP1LMNA | |
| SCHEMBL492505 | 0.84 | CYP1A2 (0.64) | MAPTCYP1A2ALDH1A1TDP1LMNA | |
| SCHEMBL1695161 | 0.84 | EGFR (0.48) | MAPTCYP1A2PDGFRBFGFR1PDGFRA | |
| SCHEMBL5201986 | 0.84 | LMNA (0.49) | MAPTCYP1A2PDGFRBFGFR1PDGFRA | |
| SCHEMBL7226743 | 0.83 | ALDH1A1 (0.50) | MAPTCYP1A2PDGFRBFGFR1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110803992-B | Preparation method of 3-nitro-4-fluoroacetophenone acetate | 暨明医药科技(苏州)有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-107108557-B | Spirocyclic indolines for the treatment and prophylaxis of Respiratory Syncytial Virus (RSV) infection | 瑞威有限公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-110803992-A | Preparation method of 3-nitro-4-fluoroacetophenone acetate | 暨明医药科技(苏州)有限公司 | 2020-02-18 | — | — | CN | disclosed |
| EP-3204375-B1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | REVIRAL LTD (GB) | 2019-02-13 | — | — | EP | disclosed |
| US-10106539-B2 | Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) | ReViral Limited (GB) | 2018-10-23 | — | — | US | disclosed |
| US-20170305908-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | ReViral Limited (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3204375-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | Reviral Limited (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055780-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | RE:VIRAL LTD (GB) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305908-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | NR3C2, SAV1, ACE2 | MAPT 4459/4885CYP1A2 585/4885PDGFRB 1557/4885 |
| US-10106539-B2 | Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) | SPTBN1, NR3C2, SPNS2 | MAPT 4479/4885CYP1A2 568/4885PDGFRB 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.